Citations 65

Clinical Characteristics of a Large Cohort of US Patients Enrolled in the National Amyotrophic Lateral Sclerosis (ALS) Registry, 2010–2015 (P4.6-001)

Neurology | December 7, 2023 | Volume: 92 | Issue: 15_supplement | Pages: No page available

10.1212/wnl.92.15_supplement.p4.6-001

Neurophysiological Correlates of Excitability in ALS: Pretreatment Findings from the Retigabine and Mexiletine-2 Studies (P1.4-005)

Neurology | December 7, 2023 | Volume: 92 | Issue: 15_supplement | Pages: No page available

10.1212/wnl.92.15_supplement.p1.4-005

Multivariate Analysis of Survival in an Amyotrophic Lateral Sclerosis Clinic Population (5268)

Neurology | December 7, 2023 | Volume: 94 | Issue: 15_supplement | Pages: No page available

10.1212/wnl.94.15_supplement.5268

COMBAT-ALS Phase 2b/3 Trial of MN-166 (Ibudilast) in ALS: Study Design and Trial Update (5149)

Neurology | December 7, 2023 | Volume: 94 | Issue: 15_supplement | Pages: No page available

10.1212/wnl.94.15_supplement.5149

Is a Personalized N-of-1 Trial Feasible to Test Shakuyakukanzoto (SKT), a Kampo (Japanese Herbal Medicine) for ALS Patients with Muscle Cramps? (4118)

Neurology | December 7, 2023 | Volume: 94 | Issue: 15_supplement | Pages: No page available

10.1212/wnl.94.15_supplement.4118

Clinical and Electrophysiological Findings in C9orf72 ALS (P2-13.006)

Neurology | December 6, 2023 | Volume: 98 | Issue: 18_supplement | Pages: No page available

10.1212/wnl.98.18_supplement.3374

Needs of persons living withALSat home and their family caregivers: A scoping review

Muscle & Nerve | May 30, 2023 | Volume: 68 | Issue: 3 | Pages: 240-249

10.1002/mus.27849 | PMID 37248728

AbstractIntroduction/AimsMost persons with amyotrophic lateral sclerosis (ALS) live at home with support of family caregivers, with escalating complexity of care over the trajectory of the disease requiring resources and support to mitigate negative physical, social, and emotional outcomes.MethodsThis scoping review identifies the home health/home care needs of persons with ALS and their caregivers as a basis for creating a home health medical standard. We used the PRISMA Extension for Scoping Reviews (PRISMA‐ScR) to examine studies describing home care needs published between 2011 and 2021.ResultsOur search yielded 481 articles, of which 44 were included with a total of 3592 (9–273) participants. Most studies used a cross‐sectional design and 20 (45%) were rated as high quality. We grouped the needs identified as emotional/psychological, assistive devices and technology, information and education, and human resources and professional services. Most studies demonstrated persistent unmet needs and that available interventions were helpful while needs generally were not met proactively, despite the predictable trajectory.DiscussionThis review describes biopsychosocial and equipment interventions over the trajectory of ALS with implications for anticipatory planning by clinicians, as well as policy for coverage of necessary services and supports. Interdisciplinary expert teams could develop consensus around needs across the trajectory and recommended services and supports. To make knowledge more accessible, encourage availability of services, and clarify the need for coverage of services, we aim to develop an expert consensus‐based ALS home health medical standard guidance document in collaboration with the American Association of Neuromuscular and Electrodiagnostic Medicine.
Results from the first four regimens of the HEALEY ALS Platform Trial (PL5.004)

Neurology | April 28, 2023 | Volume: 100 | Issue: 17_supplement_2 | Pages: No page available

10.1212/wnl.0000000000204032

Multisystem Proteinopathies (MSP) and MSP-like Disorders: Clinical-Pathological-Molecular Spectrum and Long-term Follow Up (P5-8.004)

Neurology | April 28, 2023 | Volume: 100 | Issue: 17_supplement_2 | Pages: No page available

10.1212/wnl.0000000000203494

Multisystem proteinopathies (MSPs) and MSP‐like disorders: Clinical‐pathological‐molecular spectrum

Annals of Clinical and Translational Neurology | March 2, 2023 | Volume: 10 | Issue: 4 | Pages: 632-643

10.1002/acn3.51751 | PMID 36861178

Abstract Objectives Mutations in VCP, HNRNPA2B1, HNRNPA1 , and SQSTM1 , encoding RNA‐binding proteins or proteins in quality‐control pathways, cause multisystem proteinopathies (MSP). They share pathological findings of protein aggregation and clinical combinations of inclusion body myopathy (IBM), neurodegeneration [motor neuron disorder (MND)/frontotemporal dementia (FTD)], and Paget disease of bone (PDB). Subsequently, additional genes were linked to similar but not full clinical‐pathological spectrum (MSP‐like disorders). We aimed to define the phenotypic‐genotypic spectrum of MSP and MSP‐like disorders at our institution, including long‐term follow‐up features. Methods We searched the Mayo Clinic database (January 2010–June 2022) to identify patients with mutations in MSP and MSP‐like disorders causative genes. Medical records were reviewed. Results Thirty‐one individuals (27 families) had pathogenic mutations in: VCP ( n = 17), SQSTM1 + TIA1 ( n = 5), TIA1 ( n = 5), MATR3, HNRNPA1, HSPB8 , and TFG ( n = 1, each). Myopathy occurred in all but 2 VCP ‐MSP patients with disease onset at age 52 (median). Weakness pattern was limb‐girdle in 12/15 VCP ‐MSP and HSPB8 patient, and distal‐predominant in other MSP and MSP‐like disorders. Twenty/24 muscle biopsies showed rimmed vacuolar myopathy. MND and FTD occurred in 5 (4 VCP , 1 TFG ) and 4 (3 VCP , 1 SQSTM1 + TIA1 ) patients, respectively. PDB manifested in 4 VCP ‐MSP. Diastolic dysfunction occurred in 2 VCP ‐MSP. After 11.5 years (median) from symptom onset, 15 patients ambulated without gait‐aids; loss of ambulation ( n = 5) and death ( n = 3) were recorded only in VCP ‐MSP. Interpretation VCP ‐MSP was the most common disorder; rimmed vacuolar myopathy was the most frequent manifestation; distal‐predominant weakness occurred frequently in non‐ VCP ‐MSP; and cardiac involvement was observed only in VCP ‐MSP.